PALANDRI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.317
AS - Asia 781
EU - Europa 743
SA - Sud America 88
Continente sconosciuto - Info sul continente non disponibili 28
AF - Africa 24
OC - Oceania 8
Totale 2.989
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.280
RU - Federazione Russa 302
CN - Cina 237
SG - Singapore 230
IT - Italia 200
HK - Hong Kong 85
BR - Brasile 76
KR - Corea 65
VN - Vietnam 65
IE - Irlanda 49
SE - Svezia 47
DE - Germania 41
BD - Bangladesh 29
FI - Finlandia 25
FR - Francia 23
GB - Regno Unito 21
IN - India 19
CA - Canada 18
ID - Indonesia 10
CH - Svizzera 9
TR - Turchia 9
AU - Australia 8
CI - Costa d'Avorio 8
JO - Giordania 8
JP - Giappone 6
NL - Olanda 6
UA - Ucraina 6
EC - Ecuador 5
MX - Messico 5
PL - Polonia 4
AR - Argentina 3
AT - Austria 3
HN - Honduras 3
IQ - Iraq 3
JM - Giamaica 3
NG - Nigeria 3
TH - Thailandia 3
BJ - Benin 2
BS - Bahamas 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
KE - Kenya 2
OM - Oman 2
RO - Romania 2
SV - El Salvador 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CL - Cile 1
CO - Colombia 1
CR - Costa Rica 1
DK - Danimarca 1
EG - Egitto 1
ES - Italia 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
KZ - Kazakistan 1
LB - Libano 1
MA - Marocco 1
MM - Myanmar 1
NP - Nepal 1
PS - Palestinian Territory 1
SA - Arabia Saudita 1
SC - Seychelles 1
SY - Repubblica araba siriana 1
VE - Venezuela 1
Totale 2.961
Salva come PNG Salva come JPEG
Città #
Santa Clara 459
Singapore 185
Ashburn 167
San Jose 80
Hefei 71
Hong Kong 71
Seoul 65
Chandler 63
Dublin 49
Milan 46
Beijing 40
Council Bluffs 35
Los Angeles 34
Rome 23
Ho Chi Minh City 20
Altamura 18
Lawrence 18
Lauterbourg 17
Moscow 17
New York 16
Buffalo 12
Fairfield 12
Munich 12
Princeton 11
Seattle 11
Boardman 10
Boston 10
Hanoi 10
Helsinki 10
Phoenix 10
Shanghai 10
Bern 9
Jacksonville 9
Jakarta 9
Woodbridge 9
Abidjan 8
Cambridge 8
Kent 8
Lappeenranta 8
San Diego 8
Washington 8
Melbourne 7
Mumbai 7
The Dalles 7
Wilmington 7
Dallas 6
Florence 6
Frankfurt am Main 6
London 6
Medford 6
Orem 6
São Paulo 6
Turin 6
Waltham 6
Belo Horizonte 5
Houston 5
Paris 5
Tokyo 5
Andover 4
Chennai 4
Costa Mesa 4
Düsseldorf 4
Genoa 4
Harringay 4
Izmir 4
Turku 4
Venice 4
Warsaw 4
Abuja 3
Bengaluru 3
Biên Hòa 3
Bremen 3
Brooklyn 3
Brugherio 3
Charlotte 3
Chicago 3
Da Nang 3
Falkenstein 3
Guarulhos 3
Haiphong 3
Palermo 3
Toronto 3
Vienna 3
Bari 2
Bologna 2
Columbus 2
Cotonou 2
Curitiba 2
Cusano Milanino 2
Detroit 2
Elk Grove Village 2
Guangzhou 2
Guayaquil 2
Hercules 2
Istanbul 2
Jinan 2
Johannesburg 2
Kingston 2
Manchester 2
Mexico City 2
Totale 1.917
Salva come PNG Salva come JPEG
Nome #
A modified adenine chemically coupled to the allergen molecule of Dermatophagoides pteronyssinus redirects allergen-specific Th2 cells 173
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B 2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 172
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study 168
A modified adenine chemically coupled to allergen molecule(s) induce Interferon-gamma production and down regulate IL-4 and IL-5 in Th2 specific T cells 165
COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey 164
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 163
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 155
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients 155
Total serum IgE levels influence the in vitro detection of ss-lactams-specific IgE antibodies 148
MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study 147
Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT 146
Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis 145
Incidence of blast phase in myelofibrosis according to anemia severity 144
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial 141
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib 138
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT 137
Breakthrough infections in MPN-COVID vaccinated patients 137
Long-term follow-up of recovered MPN patients with COVID-19 136
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options 109
Aspirin Regimens in EsSential thrombocythemia (ARES) Investigators. Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 22
Recommendations for best management of polycythemia vera in Italy: a Delphi consensus statement 20
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis 20
JAK inhibitor selection in challenging scenarios of myelofibrosis: a review 16
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design 16
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial 16
null 15
Health-related quality of life and symptom profile of patients with BCR::ABL1-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational study. 13
Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for essential thrombocythemia 8
Totale 2.989
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.476
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.476
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202250 0 0 3 1 0 0 0 15 1 0 9 21
2022/2023251 18 56 15 17 17 37 26 17 29 5 3 11
2023/2024160 5 11 21 16 15 27 5 37 1 10 3 9
2024/20251.002 16 67 51 118 345 188 19 36 21 20 56 65
2025/20261.227 132 170 131 71 152 29 120 56 69 94 51 152
2026/2027198 61 60 77 0 0 0 0 0 0 0 0 0
Totale 2.989